NEO ESTRONE TAB 1.25MG 1.25 MG — DIN 00287733
ESTERIFIED ESTROGENS : 1.25 MG · NEOLAB INC · TABLET · wholesale supply in Canada
Health Canada status: CANCELLED POST MARKET
What is NEO ESTRONE TAB 1.25MG?
NEO ESTRONE TAB 1.25MG 1.25 MG contains ESTERIFIED ESTROGENS : 1.25 MG. It is listed in the Health Canada Drug Product Database under DIN 00287733, held by NEOLAB INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 02-Apr-2008. This Drug Identification Number is no longer authorized for sale in Canada, so Nexara does not supply it. The record is kept here because buyers still meet the number on old formularies, purchase orders and tender documents; Nexara can help identify an authorized alternative.
What is NEO ESTRONE TAB 1.25MG used for?
NEO-ESTRONE TABLETS are prescribed in the treatment of menopausal and post menopausal symptoms including vulvar and vaginal atrophy. NEO-ESTRONE TABLETS should be prescribed with an appropriate dosage of a progestin for women with intact uteri to prevent endometrial hyperplasia/carcinoma.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Is there a generic Natural And Semisynthetic Estrogens, Plain in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
2 holders have a Canadian DIN containing Natural And Semisynthetic Estrogens, Plain, across 3 DINs, of which 0 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| SEARCHLIGHT PHARMA INC | 2 | 0 | ESTRAGYN | No marketed DIN |
| NEOLAB INC | 1 | 0 | NEO ESTRONE TAB 1.25MG | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 1.25 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Pack configuration (monograph) | null |
| Storage | NEO-ESTRONE TABLETS can be stored at room temperature (15 to 30 degrees Centigrade). |
Pack detail is kept as a regulatory record. This DIN is no longer authorized for sale in Canada, so Nexara does not quote this pack.
Substance and classification
| Active substance | Natural And Semisynthetic Estrogens, Plain |
|---|---|
| ATC code | G03CA |
| AHFS class | 88:28.01* ; See footnote |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 00287733 |
|---|---|
| DIN (unpadded, as printed on some documents) | 287733 |
| Brand name | NEO ESTRONE TAB 1.25MG |
| Generic / active ingredient | ESTERIFIED ESTROGENS : 1.25 MG |
| Market authorization holder | NEOLAB INC |
| Health Canada schedule | Prescription |
| ATC code | G03CA |
| ATC anatomical main group | G — Genito-urinary system and sex hormones |
| ATC therapeutic subgroup | G03CA |
| Current status | CANCELLED POST MARKET |
| Status date | 02-Apr-2008 |
| Original market date | 1973-12-31 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
0 of 3 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| ESTRAGYN | 0.625 MG | TABLET | SEARCHLIGHT PHARMA INC | CANCELLED POST MARKET | 00287725 |
| ESTRAGYN | 0.3 MG | TABLET | SEARCHLIGHT PHARMA INC | CANCELLED POST MARKET | 00473618 |
2 · Same class — other molecules in ATC G03CA
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Estradiol | CLIMARA 100 · CLIMARA 25 · CLIMARA 50 · CLIMARA 75 · +31 more | 51 | 22 | Yes |
| Conjugated Estrogens | APO-CONEST TAB 0.3MG · APO-CONEST TAB 0.625MG · APO-CONEST TAB 0.9MG · APO-CONEST TAB 1.25MG · +15 more | 33 | 4 | Yes |
| Estrone | ESTRAGYN VAGINAL CREAM · OESTRILIN CONES VAGINAUX · OESTRILIN CREME VAGINALE 1MG · OGEN .625 · +2 more | 6 | 1 | Yes |
| Ethinylestradiol | ESTINYL TAB 0.05MG · ESTINYL TAB 0.5MG · ESTINYL TABLETS 0.02 MG. | 3 | 0 | Not in Canada |
| Natural And Semisynthetic Estrogens, Plain | ESTRAGYN · NEO ESTRONE TAB 1.25MG | 3 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC G03C
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| G03CC | Conjugated Estrogens And Bazedoxifene | 1 | 1 |
| G03CX | Tibolone | 1 | 1 |
| G03CB | Dienestrol · Diethylstilbestrol | 4 | 0 |
4 · Fixed-dose combinations with Canadian supply
| Product | Active ingredients | Holder | Status | DIN |
|---|---|---|---|---|
| DUAVIVE | CONJUGATED ESTROGENS 0.45 MG; BAZEDOXIFENE (BAZEDOXIFENE ACETATE) 20 MG | PFIZER CANADA ULC | MARKETED | 02432854 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.